Thomas M. Brundage

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

Francisco M. Marty, Drew J. Winston, Scott D. Rowley et al. · New England Journal of Medicine · 2013 · 370 citations · Full text

Pharmacy, Immunology, Infectious Diseases +14

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

Francisco M. Marty, Drew J. Winston, Roy F. Chemaly et al. · Biology of Blood and Marrow Transplantation · 2018 · 213 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial

Michael Grimley, Roy F. Chemaly, Janet A. Englund et al. · Biology of Blood and Marrow Transplantation · 2017 · 160 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox

Greg Chittick, Marion E. Morrison, Thomas M. Brundage et al. · Antiviral Research · 2017 · 128 citations

Veterinary Medicine, Infectious Diseases, Virology +5

Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies

Timothy K. Tippin, Marion E. Morrison, Thomas M. Brundage et al. · Therapeutic Drug Monitoring · 2016 · 71 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17